NovMetaHealth

For Your Healthy Life, NovMetaHealth

NovAP

Pipeline
NovAP
Program Target
Acute Pancreatitis
Patient Numbers
2.7 Million
Development Stage
Research
NovMetaHealth develops NovAP, a new substance-based best-in-class acute pancreatitis treatment new drug.

NovAP improves mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy, which are the underlying causes of acute pancreatitis by inhibiting mitochondrial calcium channel (VDAC) protein transcription. Different from other products that control calcium channel in cell membranes, NovAP works specifically on mitochondrial calcium channels to minimize the effect on the calcium concentration of the entire cell.

NovMetaHealth identified NovLC’s superior efficacy (compared to existing medications) in animal testing and proved that it can reversibly inhibit pancreatic enzyme secretion and restore digestive enzyme secretion even after stopping the medication. NovMetaHealth, which has proven the treatment effect of NovAP for acute pancreatitis, is striving for continuous R&D.

Mechanism of action for acute pancreatitis treatment

NovAP Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Preclinical

Clinical phase 1

02

Patent Application and Registration Status
Patents IP Protection
Acute pancreatitis use patent (US)
Application
2020
Patent expiration (expected) year
(2040)